<DOC>
	<DOCNO>NCT00003951</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness DX-8951f treating patient metastatic cancer pancreas previously treat respond previous chemotherapy .</brief_summary>
	<brief_title>DX-8951f Treating Patients With Metastatic Cancer Pancreas</brief_title>
	<detailed_description>OBJECTIVES : I . Determine objective response rate patient metastatic carcinoma exocrine pancreas treat DX-8951f . II . Determine time tumor progression patient receive drug . III . Determine survival 6 12 month patient receive drug . IV . Evaluate quantitative qualitative toxicity regimen patient population . V. Evaluate pharmacokinetics drug patient population . OUTLINE : Patients receive DX-8951f IV 30 minute daily 5 day . Courses repeat every 21 day . Treatment continue absence unacceptable toxicity disease progression . Patients follow every 3 month death . PROJECTED ACCRUAL : A total 12-37 patient accrue study .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Pancrelipase</mesh_term>
	<mesh_term>Pancreatin</mesh_term>
	<mesh_term>Exatecan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm epithelial cancer exocrine pancreas Metastatic disease Previously untreated disease progressive disease firstline chemotherapy Bidimensionally measurable disease Indicator lesion must outside prior radiation port No brain metastases No islet cell tumor , lymphoma , sarcoma pancreas PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : At least 12 week Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.5 mg/dL SGOT/SGPT great 2 time upper limit normal ( ULN ) ( 5 time ULN liver metastasis present ) Renal : Creatinine great 1.5 mg/dL Cardiovascular : No active congestive heart failure No uncontrolled angina No myocardial infarction within past 6 month Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No concurrent serious infection No history malignancy within past 5 year except nonmelanoma skin cancer carcinoma situ cervix No overt psychosis , mental disability , incompetence No life threaten illness PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent biologic therapy No prophylactic colony stimulate factor prevent neutropenia Chemotherapy : See Disease Characteristics At least 4 week since prior chemotherapy recover No concurrent cytotoxic chemotherapy Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics At least 4 week since prior radiotherapy recover No concurrent radiotherapy Surgery : At least 4 week since prior major surgery recover No concurrent surgery Other : No concurrent anticancer treatment At least 28 day since prior investigational drug , include analgesic antiemetic No investigational drug 28 day study No concurrent drug induce inhibit CYP3A enzyme</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>recurrent pancreatic cancer</keyword>
	<keyword>duct cell adenocarcinoma pancreas</keyword>
	<keyword>stage IV pancreatic cancer</keyword>
</DOC>